ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2151

Effects of Methotrexate on Blood Pressure in Rheumatoid Arthritis: A Randomized Controlled Trial

Sara Tommasi1, Richard Woodman1, Michael Wiese2, Michael Shanahan1 and Arduino Mangoni1, 1Flinders University, Adelaide, Australia, 2University of South Australia, Adelaide, Australia

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, Randomized Trial, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2141–2176) RA – Treatments Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Treatment with methotrexate (MTX) has been shown to be associated with lower cardiovascular risk and lower blood pressure (BP) compared with other disease modifying anti-rheumatic drugs (DMARDs) in cross-sectional and epidemiological studies in patients with rheumatoid arthritis (RA). However, the evidence in longitudinal, randomized trials is lacking. We sought to address this issue by performing a randomized trial comparing the effect of MTX on BP against a control group on sulfasalazine.

Methods: Adult treatment-naïve patients, recently diagnosed with RA according to the 2010 ACR/EULAR criteria, were randomized to clinically guided doses of subcutaneous MTX (Group 1, n=31, age 57±15 years, 65% females) or the DMARD sulfasalazine (SSZ, Group 2, n=31, age 54±17 years, 58% females). Clinic systolic (SBP, primary study endpoint), diastolic (DBP), and mean arterial pressure (MAP), and the augmentation index (AIx), (a marker of arterial wave reflection) were measured at baseline (before treatment), and after 1 and 6 months (ClinicalTrials.gov: NCT03254589).

Results: At baseline, the two groups were matched for age, gender, body mass index, and 28-joint disease activity score (p>0.05 for all comparisons). After 1 month of treatment, group 1 had a trend towards a significant reduction in SBP (mean difference -2.6±10.6 mmHg, p=0.09) and DBP (mean difference -1.8±6.7 mmHg, p = 0.053) and a significant reduction in MAP (mean difference -2.1±7.5 mmHg, p=0.049) compared to Group 2. After 6 months of treatment, group 1 had a significant reduction in SBP (mean difference -4.0±10.8 mmHg, p=0.038) and MAP (mean difference -4.3±17.9 mmHg, p=0.023) and a trend towards a significant reduction in DBP (mean difference -0.7±6.82 mmHg, p=0.053). There were no significant between-group differences in AIx over time.

Conclusion: The results of this study provide the first evidence that MTX treatment causes a significant reduction in SBP (primary endpoint) at 6 months in RA patients in intervention studies. The effects of MTX on BP are not mediated by changes in arterial wave reflections. Further research is warranted to identify the mechanisms involved in the MTX-induced BP lowering effects and whether such effects account for the protective effects of MTX against cardiovascular disease observed in RA.

Supporting image 1

Supporting image 2


Disclosures: S. Tommasi: None; R. Woodman: None; M. Wiese: None; M. Shanahan: None; A. Mangoni: None.

To cite this abstract in AMA style:

Tommasi S, Woodman R, Wiese M, Shanahan M, Mangoni A. Effects of Methotrexate on Blood Pressure in Rheumatoid Arthritis: A Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/effects-of-methotrexate-on-blood-pressure-in-rheumatoid-arthritis-a-randomized-controlled-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-methotrexate-on-blood-pressure-in-rheumatoid-arthritis-a-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology